Sohu.com Ltd (SOHU): Financial results for Q2 2026

Sohu.com (SOHU), Onity Group (ONIT), and TriMas (TRS) trade at low P/E ratios (1.6x, 2.3x, 1.6x respectively) despite showing signs of business strength. SOHU reported 7% YOY revenue growth and improved profitability. ONIT saw 24% YOY revenue growth and 64% origination growth but faced servicing headwinds. TRS showed 1.6% YOY sales growth and 29% operating profit increase, with raised earnings guidance.

Sohu.com Limited (SOHU) reported Q2 2026 revenue of $136 million, up 7% YoY but down 4% QoQ. Online games were $116 million, up 10% YoY, while marketing services were $15 million. GAAP net income was $0.2 million after a ~$30 million tax reversal; non-GAAP net income was $0.5 million. The company also said it repurchased 9.4M ADS for ~$124M and authorized more up to $150M. Q3 guidance: marketing services $40M-$50M; online games $105M-$150M.

Sohu.com (NASDAQ:SOHU) reported Q2 call highlights, citing sequential growth in marketing services revenue but a weak advertising environment as advertisers stay cautious and shift toward social and influencer-driven marketing. Management forecast Q3 marketing services revenue of $40M-$50M, online game revenue $105M-$115M, and GAAP/non-GAAP net loss of $30M-$23M. Sohu repurchased 9.4M ADS for about $124M, with up to $150M authorized.

Sohu.com Limited (NASDAQ: SOHU) reported Q2 2026 unaudited results. Total revenue was $136m, up 7% YoY and down 4% QoQ. GAAP net income was $0.2m after a ~$13m tax expense reversal; non-GAAP net income was $0.5m. The board amended its ADS repurchase program to open-ended; $124m spent on 9.4m ADS as of Aug 6. Q3 guidance: marketing $14m-$15m, online games $105m-$115m, GAAP/non-GAAP net loss $13m-$23m.

Apple raised MacBook and iPad prices by up to $300 on June 25, citing higher memory and storage chip costs tied to AI data-center demand; its shares closed down more than 6%. Microsoft followed with Xbox price increases of $100–$150 effective Aug. 1; its stock fell 3.5%. The announcements helped drive an Asian selloff, with South Korea’s KOSPI dropping to about 8,600 early, and chip stocks like SK Hynix and Samsung down over 4%.

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.